In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protiva Biotherapeutics Inc.

Division of Arbutus Biopharma Corp.

Latest From Protiva Biotherapeutics Inc.

Alnylam adds over $80M to warchest to advance lead RNAi programmes

Alnylam Pharmaceuticals, a pioneer in RNA interference ("gene silencing"), has raised $92.7 million in a public offering that was well received by the market. The offered shares were priced at $10.75 per share, a 13% discount to the prevailing price on 13 February, and the company’s stock price fell quickly to around $11.0 on 14 February. However, it quickly rebounded to close on 16 February at $12.59.

Cardiovascular Metabolic Disorders

RNAi Creates Novel Court Filings; Tekmira In Trade Secrets Dispute With AlCana

A British Columbia court orders AlCana to return thousands of documents it allegedly downloaded from Tekmira’s electronic document management system. The claim arose from Tekmira’s suit against Alnylam and AlCana alleging trade secrets theft.

BioPharmaceutical Legal Issues

Executive Briefing - Oligonucleotide therapeutics: the next big thing

1953 was an extraordinary year for biology, an annus mirabilis, or wonder year, which offered scientific insights to rival those made by Einstein almost half a century earlier.

Metabolic Disorders Cardiovascular

Traversa Therapeutics Inc

Traversa aims to solve a fundamental problem: the adequate delivery of short interfering RNA molecules to a wide range of cell types via a non-cytoxic mechanism.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Arbutus Biopharma Corp.
  • Senior Management
  • Mark J Murray, PhD, Pres. & CEO
    Ian McLachlan, PhD, CSO
  • Contact Info
  • Protiva Biotherapeutics Inc.
    Phone: (604) 630-5061
    100-3480 Gilmore Way
    Burnaby, V5G 4W7